It has been suggested that the bioactive lipid mediator oleoylethanolamide (OEA), a potent agonist of the peroxisome proliferator-activated receptor-alpha (PPAR-α) possesses anti-depressant-like effects in several preclinical models. We recently demonstrated that several of OEA's behavioural actions require the integrity of the brain histaminergic system, and that an intact histaminergic neurotransmission is specifically required for selective serotonin re-uptake inhibitors to exert their anti-depressant-like effect. The purpose of our study was to test if OEA requires the integrity of the histaminergic neurotransmission to exert its antidepressant-like effects. Immobility time in the tail suspension test was measured to assess OEA's potential (10 mg/kg i.p.) as an antidepressant drug in histidine decarboxylase null (HDC−/-) mice and HDC+/+ littermates, as well as in PPAR-α+/+ and PPAR-α−/− mice. CREB phosphorylation was evaluated using Western blot analysis in hippocampal and cortical homogenates, as pCREB is considered partially responsible for the efficacy of antidepressants. Serotonin release from ventral hippocampi of HDC+/+ and HDC−/- mice was measured with in-vivo microdialysis, following OEA administration. OEA decreased immobility time and increased brain pCREB levels in HDC+/+ mice, whereas it was ineffective in HDC−/- mice. Comparable results were obtained in PPAR-α+/+ and PPAR-α−/− mice. Microdialysis revealed a dysregulation of serotonin release induced by OEA in HDC−/- mice. Our observations corroborate our hypothesis that brain histamine and signals transmitted by OEA interact to elaborate appropriate behaviours and may be the basis for the efficacy of OEA as an antidepressant-like compound.

Histamine-deficient mice do not respond to the antidepressant-like effects of oleoylethanolamide / Alessia Costa, Claudia Cristiano, Tommaso Cassano, Cristina Anna Gallelli, Silvana Gaetani, Carla Ghelardini, Patrizio Blandina, Antonio Calignano, Maria Beatrice Passani, Gustavo Provensi. - In: NEUROPHARMACOLOGY. - ISSN 0028-3908. - STAMPA. - 135:(2018), pp. 234-241. [10.1016/j.neuropharm.2018.03.033]

Histamine-deficient mice do not respond to the antidepressant-like effects of oleoylethanolamide

Alessia Costa;Silvana Gaetani;Carla Ghelardini;Patrizio Blandina;Maria Beatrice Passani;Gustavo Provensi
2018

Abstract

It has been suggested that the bioactive lipid mediator oleoylethanolamide (OEA), a potent agonist of the peroxisome proliferator-activated receptor-alpha (PPAR-α) possesses anti-depressant-like effects in several preclinical models. We recently demonstrated that several of OEA's behavioural actions require the integrity of the brain histaminergic system, and that an intact histaminergic neurotransmission is specifically required for selective serotonin re-uptake inhibitors to exert their anti-depressant-like effect. The purpose of our study was to test if OEA requires the integrity of the histaminergic neurotransmission to exert its antidepressant-like effects. Immobility time in the tail suspension test was measured to assess OEA's potential (10 mg/kg i.p.) as an antidepressant drug in histidine decarboxylase null (HDC−/-) mice and HDC+/+ littermates, as well as in PPAR-α+/+ and PPAR-α−/− mice. CREB phosphorylation was evaluated using Western blot analysis in hippocampal and cortical homogenates, as pCREB is considered partially responsible for the efficacy of antidepressants. Serotonin release from ventral hippocampi of HDC+/+ and HDC−/- mice was measured with in-vivo microdialysis, following OEA administration. OEA decreased immobility time and increased brain pCREB levels in HDC+/+ mice, whereas it was ineffective in HDC−/- mice. Comparable results were obtained in PPAR-α+/+ and PPAR-α−/− mice. Microdialysis revealed a dysregulation of serotonin release induced by OEA in HDC−/- mice. Our observations corroborate our hypothesis that brain histamine and signals transmitted by OEA interact to elaborate appropriate behaviours and may be the basis for the efficacy of OEA as an antidepressant-like compound.
2018
135
234
241
Goal 3: Good health and well-being for people
Alessia Costa, Claudia Cristiano, Tommaso Cassano, Cristina Anna Gallelli, Silvana Gaetani, Carla Ghelardini, Patrizio Blandina, Antonio Calignano, Maria Beatrice Passani, Gustavo Provensi
File in questo prodotto:
File Dimensione Formato  
2018 Costa et al. Neuropharmacology.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 885.03 kB
Formato Adobe PDF
885.03 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1126687
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact